Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.01), $0.15 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $70.77 million versus the consensus estimate of $58.98 million.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.